Obsidian Therapeutics is a pre-revenue biotechnology stock down 73% from its high, with quality below the engine's floor and momentum failing, so the large analyst upside is not enough to justify a position.
Thesis pillars
- Quality Below Floor→Stable
- Momentum Gate Failing→Stable
- Large Analyst Upside→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 4, 2026
Obsidian Therapeutics, Inc. (OBX) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $14.59: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 8.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced... Read more
Sell if holding. Engine safety override at $14.59: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 8.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.0/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Obsidian Therapeutics, Inc.
Latest news
- NEWS Obsidian Therapeutics To Present Updated Data In Patients With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma F — benzinga Oct 2, 2026 positive
- NEWS Leerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32 — benzinga Sep 22, 2026 positive
- NEWS Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday — benzinga Sep 8, 2026 positive
- NEWS Obsidian Therapeutics Files Prospectus Related To Resale Of Up To 29,164,045 Shares Of Common Stock By Selling Stockhold — benzinga Aug 28, 2026 negative
- NEWS Duos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Movin — benzinga Aug 18, 2026 neutral
Generated 2026-10-29T11:14:34Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $14.59: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 8.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $13.57. Score 6.0/10, moderate confidence.
Analyst target: $33.15 (+127.2% upside). Prior stop was $13.57. Stop-loss: $13.57.
Quality below floor (3.0 < 4.0).
Obsidian Therapeutics, Inc. trades at a P/E of N/A (forward -6.8). TrendMatrix value score: 9.0/10. Verdict: Sell.
9 analysts cover OBX with a consensus score of 4.2/5. Average price target: $39.
What does Obsidian Therapeutics, Inc. do?Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene...
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.